Dr. Steve O’Day discusses the current state of cancer treatments, which focuses less on standard chemotherapy and has begun relying more on targeted therapies and immune-oncology.
Dr. S. Yosuf Zafar provides an overview of the advancement of precision medicine and points out the importance of making sure treatment decisions are in line with the patient’s goals.
Dr. Jorge Cortes provides examples of how personalized or precision medicine has positively impacted the approach to cancer care, citing the benefits of FLT3 inhibitors, IDH inhibitors, and MEK inhibitors, and other targeted treatments.
Dr. Jorge Cortes discusses how to improve the current standard of care by better utilizing the drugs and treatments that are already available.
Dr. Alex Adjei shares an example of how precision medicine has drastically improved the quality of life for many cancer patients, but stresses the need to find more and better approaches to treating various cancer types.
Dr. Alex Adjei discusses how the standard of care for cancer patients has improved overt he last few years, but there is still a great need for new treatments designed to help a broader range of cancer patients.
Dr. Jennifer R. Brown deliberates on the state of personalized medicine in relation to CLL. She explains that the targeted drugs currently used for CLL actually work for most patients, rather than just a subgroup. Also, CLL therapies are now generally in pill form and well tolerated with few side [ Read More ]
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr. Stainthorpe explains that when it comes to bringing personalized medicines to fruition, the challenge is the same worldwide. It is an effort that requires better understanding of disease pathways and markers as well as improved diagnostics.
Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.